New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
11:48 EDTBMYBristol-Myers recalls Coumadin for injection after particulate matter found
Bristol-Myers Squibb is voluntarily recalling six lots of Coumadin for injection, 5 mg single-use vials in the U.S. the FDA announced. This recall is a precautionary measure based on the company's investigation of visible particulate matter found in a small number of Coumadin for injection unreleased samples. Bristol-Myers Squibb believes the safety risk to patients is low, and is further mitigated by the product's prescribing information advising that intravenous drug products be inspected visually prior to administration. Coumadin for injection was discontinued in early April and the oral formulation, Coumadin tablets, is not impacted by this recall, the FDA noted.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
11:31 EDTBMYLion Biotechnologies TIL combo data an 'important' positive, says Piper Jaffray
After Lion Biotechnologies (LBIO) announced the report of positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, in combination with Bristol-Myers' (BMY) Yervoy in patients with metastatic melanoma, Piper Jaffray noted that the success rate for receiving TIL combo treatment was significantly higher than the prior result for TIL monontherapy. Piper said this fact highlights the combo approach may drive significantly broader application of TIL than it initially expected and the firm reiterated its Overweight rating and $21 price target on Lion shares.
March 26, 2015
07:30 EDTBMYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
March 20, 2015
07:55 EDTBMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use